<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00531193</url>
  </required_header>
  <id_info>
    <org_study_id>204HV101</org_study_id>
    <secondary_id>EUDRACT 2007-001575-10</secondary_id>
    <nct_id>NCT00531193</nct_id>
  </id_info>
  <brief_title>Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers</brief_title>
  <official_title>An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of BIIB014 at Multiple Dose Levels in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish the extent to which BIIB014, following 8 to 12 consecutive days of dosing at&#xD;
      selected dose levels, occupies the brain's A2A receptors. Receptor occupancy will be assessed&#xD;
      by PET scanning using a radiolabelled tracer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be enrolled sequentially into cohorts of 2 to 4 subjects. PET scan results will&#xD;
      determine the actual number of cohorts enrolled and the BIIB014 dose given to each subject.&#xD;
      Since all enrolled subjects will be receiving BIIB014, this study is being listed as a 1-arm,&#xD;
      Single Group study (actual study design is dose escalation).&#xD;
&#xD;
      Participating subjects will be required to reside in the clinical unit for 10 to 14&#xD;
      consecutive days. Participants will receive 1 oral dose of BIIB014 daily for 8 to 12&#xD;
      consecutive days. During the study, subjects will undergo 2 PET scans and 1 MRI. Frequent&#xD;
      blood sample for pharmacokinetic assessments will also be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PET scanning with [11C]SCH442416 of the putamen, caudate, nucleus accumbens, thalamus, and cerebellum.</measure>
    <time_frame>pre-dose and 24h following last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentrations of BIIB014 and its N-acetyl metabolite will be measured in blood plasma</measure>
    <time_frame>up to 24h following last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Various protocol-specified doses of BIIB014 will be used (doses to be determined by PET scan results)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB014</intervention_name>
    <description>oral administration of BIIB014, given once daily for 8 to 12 consecutive days, at various doses as specified in protocol</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[11C]SCH442416</intervention_name>
    <description>11C]SCH442416 is a radiolabelled tracer molecule that specifically binds to adenosine A2A sites and will be used to evaluate receptor occupancy. The target activity will be 370 MBq. [11C]SCH442416 will be administered IV as a bolus injection over 30 seconds following the start of each PET scan.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI between 18.0 and 29.0 kg/m2&#xD;
&#xD;
          -  Willing to abstain from caffeine-containing products from 1 week prior to dosing until&#xD;
             discharge from unit.&#xD;
&#xD;
          -  Willing and able to practice effective contraception until 2 months following last&#xD;
             dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of severe allergic reactions or clinically significant allergies.&#xD;
&#xD;
          -  History of malignancy, excluding adequately treated basal cell carcinoma.&#xD;
&#xD;
          -  History of any clinically significant disease.&#xD;
&#xD;
          -  History of claustrophobia or any condition incompatible with MRI/PET scanning.&#xD;
&#xD;
          -  History of any exposure to ionizing radiation, with the exception of dental x-rays,&#xD;
             within the 12 months prior to dosing.&#xD;
&#xD;
          -  Serious infection within the 4 weeks prior to dosing.&#xD;
&#xD;
          -  HbA1c &gt; 6%, positive for Hepatitis C or Hepatitis B, presence of HIV or known exposure&#xD;
             to HIV, positive G6PD assay, or any other clinically significant abnormal laboratory&#xD;
             parameters at Screening.&#xD;
&#xD;
          -  Abnormal supine or standing blood pressure or orthostatic hypotension.&#xD;
&#xD;
          -  Any prior treatment with antipsychotic medications, dopamine antagonists, or&#xD;
             dopaminergic agonists.&#xD;
&#xD;
          -  Treatment with any other investigational drug within 3 months prior to dosing.&#xD;
&#xD;
          -  Treatment with any prescription medications within 4 weeks prior to dosing.&#xD;
&#xD;
          -  History of drug or alcohol abuse within 1 year prior to dosing.&#xD;
&#xD;
          -  Current smoker or any tobacco use within 3 months prior to dosing.&#xD;
&#xD;
          -  Heavy caffeine consumption within 4 weeks prior to dosing.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biogen Idec</last_name>
    <role>Study Director</role>
    <affiliation>Cambridge, MA USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>September 17, 2007</study_first_submitted>
  <study_first_submitted_qc>September 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2007</study_first_posted>
  <last_update_submitted>July 29, 2008</last_update_submitted>
  <last_update_submitted_qc>July 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2008</last_update_posted>
  <responsible_party>
    <name_title>Biogen Idec MD</name_title>
    <organization>Biogen Idec</organization>
  </responsible_party>
  <keyword>Healthy male volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H-(1,2,3)triazolo(4,5-d)pyrimidine-5-amine</mesh_term>
    <mesh_term>SCH 442416</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

